viewPredictmedix Inc.

Predictmedix collaborating with Tech Mahindra on workplace impairment and COVID-19 detection technology

Predictmedix says impairment caused by cannabis and alcohol is a major workplace health and safety issue

The technology is to be deployed using a software-as-a-service (SaaS) model on a revenue-sharing basis

Predictmedix Inc (CSE:PMED) (OTCQB:PDMEF) is collaborating with Tech Mahindra Ltd to offer artificial-intelligence-based healthcare solutions as a part of a suite of post-COVID-19 technologies.

Predictmedix said Tech Mahindra’s technologies focus on workplace health and safety, as underscored by the coronavirus (COVID-19) pandemic.

Since June, both companies have been working closely to incorporate Predictmedix's impairment detection technology along with its COVID-19 solutions into Tech Mahindra’s Health NxT platform.

WATCH: Predictmedix files two U.S. patents for technology while seeing big growth potential in Europe

“As part of Tech Mahindra Health NxT platform, we are leveraging the power of digital technologies including artificial intelligence and machine learning to augment our virtual health solutions, which will support health care providers and organizations to manage COVID-19 pandemic,” said Venugopal Reddy Kandimalla, senior vice president at Tech Mahindra, in a statement.

“While innovating in this space, we are also collaborating with partners with niche solutions to enhance our COVID suite of solutions for different markets on a regular basis."

Predictmedix said impairment caused by cannabis and alcohol is a major workplace health and safety issue.

As a result, the company has developed a proprietary technology that uses multispectral cameras and can be deployed in a workplace setting to screen for both cannabis and alcohol impairment along with screening for COVID-19 symptoms. Its technology uses facial and voice recognition to identify impairment.

Toronto-based Predictmedix said the technology is to be deployed using a software-as-a-service (SaaS) model on a revenue-sharing basis, which will involve an upfront customization fee followed by a monthly license fee based on the volume of screenings.

"The current COVID-19 pandemic has really brought upon an increased focus on workplace health and safety and our impairment detection along with COVID-19 symptom screening technologies fit in well with the suite of technologies being assembled by Tech Mahindra," said Dr Rahul Kushwah, chief operating officer of Predictmedix.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham


Quick facts: Predictmedix Inc.

Price: 0.325 CAD

Market: CSE
Market Cap: $33.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Predictmedix Inc. named herein, including the promotion by the Company of Predictmedix Inc. in any Content on the Site, the Company receives...


PredictMedix looking to leverage platform to become industry leader in 3 AI...

PredictMedix (CSE: PMED-OTCQB: PMEDF) CEO Dr. Rahul Kushwah joined Steve Darling from Proactive Vancouver to provide an update on the many milestones the company has hit so far this year. Dr. Kushwah telling Proactive about each of their verticals and also commenting on the many contracts...

3 weeks, 6 days ago

2 min read